Boehringer Threatens Turkish Exit Due To Price Cuts
This article was originally published in PharmAsia News
Executive Summary
German drug maker Boehringer Ingelheim GMBH, dismayed by profit declines caused by a series of price cut measures enforced by the Turkish government, has indicated it is considering quitting the Turkish market, but it still hopes to continue research and investment in one of the fastest growing pharmaceutical markets
You may also be interested in...
Red Alert For Pharma As Turkey Cuts Drug Reimbursements In Next Budget
The government hopes to cut its budget for drug reimbursements despite rising demand sparked by health care reforms.
Amgen Shrugs Off Turkish Price Cuts, Snatches Up Mustafa Nevzat For Broader Reach Into Emerging Markets
Despite harsh price cuts in Turkey that have taken a toll on multinationals, Amgen dives head first into the market.
With December Approaching, Are More Turkish Price Cuts On The Way?
Turkey has attracted considerable attention in recent years from multinational pharmaceutical companies looking to grow in emerging markets. But the government of the world's 12-largest pharmaceutical market has also enforced steep price cuts on drugs in each of the last two years, both times in December. With December quickly approaching, are a new round of price cuts on the horizon